E
Evangelos Terpos
Researcher at National and Kapodistrian University of Athens
Publications - 858
Citations - 33515
Evangelos Terpos is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 73, co-authored 725 publications receiving 25857 citations. Previous affiliations of Evangelos Terpos include Hammersmith Hospital & Imperial College London.
Papers
More filters
Journal ArticleDOI
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Efstathios Kastritis,Ioannis Kostopoulos,Evangelos Terpos,Bruno Paiva,Despina Fotiou,Maria Gavriatopoulou,Nikolaos Kanellias,Dimitrios C. Ziogas,Maria Roussou,Magdalini Migkou,Evangelos Eleutherakis-Papaiakovou,Ioannis P. Trougakos,Ourania E. Tsitsilonis,Meletios A. Dimopoulos +13 more
TL;DR: Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis and its effects on survival and quality of life is evaluated.
Journal ArticleDOI
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.
Efstathios Kastritis,Marie-Christine Kyrtsonis,Pierre Morel,Maria Gavriatopoulou,Evdoxia Hatjiharissi,Argirios S. Symeonidis,Amalia Vassou,Panagiotis Repousis,Sossana Delimpasi,Anastasia Sioni,Evrydiki Michalis,Michail Michael,Elina Vervessou,Michael Voulgarelis,Constantinos Tsatalas,Evangelos Terpos,Meletios A. Dimopoulos +16 more
TL;DR: In many patients, other factors rather than WM or its treatment may be the cause of death, and non-WM-related mortality mainly affects outcomes of elderly patients and is non- WM-related.
Journal ArticleDOI
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Sara Bringhen,Alberto Milan,Mattia D'Agostino,Claudio Ferri,Ralph Wäsch,Alessandra Larocca,Massimo Offidani,Sonja Zweegman,Evangelos Terpos,Hartmut Goldschmidt,Michele Cavo,Heinz Ludwig,Christoph Driessen,Holger W. Auner,Jo Caers,Martin Gramatzki,Meletios A. Dimopoulos,Mario Boccadoro,Hermann Einsele,Pieter Sonneveld,Monika Engelhardt +20 more
TL;DR: The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma patients and produces impressive response rates in newly diagnosed MM patients.
Journal ArticleDOI
The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
Evangelos Terpos,Dimitrios Christoulas,Efstathios Kastritis,Eirini Katodritou,Anastasia Pouli,Eurydiki Michalis,Ioannis Papassotiriou,Meletios A. Dimopoulos +7 more
TL;DR: The aim of this study was to prospectively evaluate, for the first time in the literature, the CKD‐EPI‐sCR‐CysC formula in newly diagnosed patients with symptomatic MM.
Journal ArticleDOI
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
Noopur Raje,Philippe Moreau,Evangelos Terpos,Lotfi Benboubker,Norbert Grząśko,Sarah A. Holstein,Albert Oriol,Shang-Yi Huang,Meral Beksac,Kazimierz Kuliczkowski,Datchen Fritz Tai,James E. Wooldridge,Ilaria Conti,Christopher Kaiser,Tuan S. Nguyen,Damien M. Cronier,Antonio Palumbo +16 more
TL;DR: Although generally well tolerated, PFS was not improved during treatment with tabalumab compared to placebo, and BAFF appears to have some prognostic value in patients with multiple myeloma.